Move of the month

Dr Joerg Moeller appointed CEO of BenevolentAI

BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as its new chief executive officer and executive board member, the changes will be effective immediately.
Joerg Moeller brings with him multiple years of experience, having led global research and development (R&D) organisations, and working within commercial and operational roles. He has previous experience in drug discovery collaborations with artificial intelligence (AI) companies.
Previously he has worked as executive vice president (EVP), head of global R&D and member of the Global Leadership Team at LEO Pharma A/S. Prior to this he worked at Bayer AG for over twenty years, holding various leadership roles, including EVP, head of Pharmaceuticals Research and Development and member of the Executive Committee of the pharmaceuticals division of Bayer.
Commenting on his appointment, Dr Joerg Moeller stated: “I am excited by the opportunity to lead BenevolentAI. I believe the company is well-positioned to further capitalise on its platform, pipeline and research capabilities in order to strengthen the company’s market position and continue to build its commercial activities. I am passionate about fostering a culture of excellence, innovation, and diversity and I look forward to working with the board, the leadership team and BenevolentAI employees to create value for all its stakeholders ultimately helping to deliver treatments to the patients who need them.”
Dr François Nader, chair of BenevolentAI, added: “Along with the rest of the board, I am delighted to welcome Joerg. Joerg is an outstanding leader with extensive experience across all stages of R&D. He is a strong advocate of AI as a driver of discovery innovation and effectiveness. With his track record of delivering growth through driving performance, I am confident that Joerg will leverage our proprietary and validated Benevolent Platform to deliver our patient-centric revenue generating strategy.”